Home › Eierstokkanker › Michigan › Detroit
Eierstokkanker klinische studies in Detroit, MI
26 studies voor Eierstokkanker zoeken deelnemers op locaties in en rond Detroit (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruterenGezonde vrijwilligers welkom
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RekruterenFase 2/3
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekruterenFase 1/2
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RekruterenObservatieonderzoek
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekruterenFase 2
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruterenFase 3
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruterenFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekruterenFase 2
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekruterenFase 3
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekruterenFase 2
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruterenFase 1
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekruterenFase 3
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RekruterenFase 1
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruterenFase 3
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruterenFase 1/2
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RekruterenFase 2
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
RekruterenFase 2
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
Eierstokkanker studies in andere steden
- Houston, TX89 studies
- New York City, NY69 studies
- Boston, MA61 studies
- Los Angeles, CA50 studies
- Nashville, TN49 studies
- Arlington, VA46 studies
- Philadelphia, PA44 studies
- Columbus, OH39 studies
- St. Louis, MO38 studies
- Chicago, IL36 studies
- San Antonio, TX31 studies
- Cleveland, OH30 studies
Andere studies in Detroit
- Niet-kleincellige longkanker44 studies
- Borstkanker33 studies
- Kanker (alle vormen)29 studies
- Colorectale kanker26 studies
- Metastatische kanker24 studies
- Prostaatkanker22 studies
- Endometriumkanker21 studies
- Longkanker20 studies
- Multipel myeloom19 studies
- Maagkanker16 studies
- Plaveiselcelcarcinoom van hoofd en hals15 studies
- Acute myeloïde leukemie14 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.